---
title: "Hangzhou Biotest Biotech Co.,Ltd. (688767.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688767.SH.md"
symbol: "688767.SH"
name: "Hangzhou Biotest Biotech Co.,Ltd."
industry: "Biotechnology"
datetime: "2026-05-19T23:11:50.023Z"
locales:
  - [en](https://longbridge.com/en/quote/688767.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688767.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688767.SH.md)
---

# Hangzhou Biotest Biotech Co.,Ltd. (688767.SH)

## Company Overview

Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, biochemistry, and various infectious diseases. It also provides veterinary test kits; fluorescence immunoassay rapid test kits; and other rapid testing kits.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.biotests.com.cn](https://www.biotests.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: C (0.53)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 47 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -12.15% |  |
| Net Profit YoY | -78.13% |  |
| P/B Ratio | 2.65 |  |
| Dividend Ratio | 1.71% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6242140293.77 |  |
| Revenue | 449073157.14 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 1.27% | D |
| Profit Margin | 6.74% | B |
| Gross Margin | 47.56% | B |
| Revenue YoY | -12.15% | E |
| Net Profit YoY | -78.13% | E |
| Total Assets YoY | -2.27% | D |
| Net Assets YoY | -2.47% | D |
| Cash Flow Margin | 200.92% | B |
| OCF YoY | -12.15% | E |
| Turnover | 0.18 | D |
| Gearing Ratio | 4.90% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hangzhou Biotest Biotech Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-12.15%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-78.13%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.65",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.71%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6242140293.77",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "449073157.14",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "1.27%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "6.74%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "47.56%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-12.15%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-78.13%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.27%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-2.47%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "200.92%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-12.15%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.18",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "4.90%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 201.24 | 40/81 | 58.89 | 54.16 | 38.75 |
| PB | 2.58 | 38/81 | 2.66 | 2.43 | 2.18 |
| PS (TTM) | 13.57 | 59/81 | 12.76 | 11.84 | 10.14 |
| Dividend Yield | 1.75% | 18/81 | 2.91% | 2.56% | 1.99% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688767.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688767.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688767.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**